Blenrep alternatives
9 products to explore · 2026
Your shortlist, at a glance.
Read the comparisons ↓Check each product’s website for current pricing and features. A verified badge indicates a verified listing, not a ranking.
About Blenrep and its alternatives
Patients and oncologists researching Blenrep alternatives often seek other multiple myeloma therapies with different mechanisms, safety profiles or dosing schedules. Blenrep is GSK's antibody-drug conjugate targeting BCMA for relapsed or refractory cases. People compare options based on progression-free survival data, ocular side-effect management, infusion requirements and combination potential with standard-of-care regimens. Long-tail searches frequently include questions around switching after belantamab mafodotin discontinuation, real-world outcomes versus other BCMA-directed agents, and access programs for subsequent lines of therapy in heavily pretreated patients.
Explore the alternatives
- V
1.Valink Therapeutics
Healthcare & MedicalDiscovering bispecific antibody drug-conjugates (BsADC) against cancer
2.Adcetris
Healthcare & MedicalOncology therapy developed through rigorous clinical research
- F
3.Farxiga
Healthcare & MedicalScience-led biopharmaceutical medicine for cardiovascular, renal and metabolic conditions.
4.Gilead Sciences (Kite Pharma)
Healthcare & MedicalBiopharma leader advancing therapies in virology, oncology and inflammation
- I
5.ImmunoGen
Healthcare & MedicalImmunoGen
6.Mersana Therapeutics
Healthcare & MedicalNovel ADC programs advancing cancer treatment after Day One acquisition
7.Roche Ventana
Healthcare & MedicalDoing now what patients need next
8.Sutro Biopharma
Healthcare & MedicalClinical-stage biotech advancing next-generation ADCs via cell-free XpressCF platform
9.Zymeworks
Healthcare & MedicalRoyalty-driven biotech developing antibody medicines for hard-to-treat cancers
See more comparisons in Healthcare & Medical alternatives.
Questions about Blenrep alternatives
What are the main clinical differences between Blenrep and other BCMA-targeted myeloma therapies?
Blenrep uses an antibody-drug conjugate platform with a specific payload and dosing schedule that requires eye monitoring, unlike some bispecific antibodies or CAR-T options that carry different cytokine-release and manufacturing considerations.
How do oncologists decide when to switch from Blenrep to an alternative myeloma treatment?
Decisions typically factor in response duration, ocular toxicity management, patient fitness for CAR-T or bispecific therapy, and availability of clinical trials or expanded-access programs.
Are there oral alternatives to Blenrep for relapsed multiple myeloma?
Several oral immunomodulatory agents and proteasome inhibitors are used in earlier lines or combinations, though they differ in mechanism and are often sequenced based on prior exposure rather than direct head-to-head replacement.
What access programs exist for patients discontinuing Blenrep due to side effects?
GSK and other manufacturers offer patient-support services, compassionate-use pathways and co-pay assistance that vary by region and insurance status for subsequent approved myeloma agents.
How does Blenrep's real-world ocular toxicity profile compare with other approved options?
Blenrep requires regular ophthalmic exams because of keratopathy risk, a consideration weighed against neurotoxicity or infection risks seen with certain bispecific or CAR-T alternatives.